12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fovista: Phase IIb data

A double-blind, U.S. Phase IIb trial in 449 patients with neovascular wet AMD showed that once-monthly 1.5 mg/eye intravitreal Fovista plus Lucentis ranibizumab met the primary endpoint of improving mean visual acuity as measured by the ETDRS eye chart from baseline to week 24 vs. Lucentis alone (10.6 vs. 6.5 letters gained, p=0.019). Additionally, high-dose Fovista plus Lucentis led to an average absolute improvement in visual acuity from baseline of 7.4% compared to Lucentis alone in...

Read the full 369 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >